• 1
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 265566.
  • 2
    Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al, for the Scleroderma Lung Study Group. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005; 52: 592600.
  • 3
    Tsevat J, Weeks JC, Guadagnoli E, Tosteson AN, Mangione CM, Pliskin JS, et al. Using health-related quality-of-life information: clinical encounters, clinical trials, and health policy. J Gen Intern Med 1994; 9: 57682.
  • 4
    Khanna D. Health-related quality of life: a primer with focus on scleroderma. Scleroderma Care Res [article online]. 2006; 3: 313. URL:
  • 5
    Tsevat J. What do utilities measure? Med Care 2000; 38 Suppl : 9 II 1604.
  • 6
    Khanna D, Ahmed M, Furst DE, Ginsburg SS, Park GS, Hornung R, et al. Health values of patients with systemic sclerosis. Arthritis Rheum 2007; 57: 8693.
  • 7
    Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life [review]. J Clin Epidemiol 2003; 56: 31725.
  • 8
    Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 health survey. J Clin Epidemiol 1998; 51: 111528.
  • 9
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 40715.
  • 10
    Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006; 65: 13259.
  • 11
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 12
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 13
    Ware JE Jr, Kosinki M, Keller S. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute, New England Medical Center; 1994.
  • 14
    Ware J, Kosinski M, Dewey J. How to score version two of the SF-36 health survey. Lincoln (RI): QualityMetric; 2000.
  • 15
    Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 147887.
  • 16
    Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001; 45: 38491.
  • 17
    Strand V, Crawford B. Improvement in the health-related quality of life in patients with SLE following sustained reductions in anti-DNA antibodies. Expert Rev Pharmacoecon Outcomes Res 2005; 5: 31726.
  • 18
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 19
    Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. Correlates of the disability index of the Health Assessment Questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999; 42: 237280.
  • 20
    Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire disability index in a systemic sclerosis clinical trial. J Rheumatol 2005; 32: 83240.
  • 21
    Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 55760.
  • 22
    Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 7518.
  • 23
    Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56: 24855.
  • 24
    Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 27192.
  • 25
    Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D [review]. Qual Life Res 2005; 14: 152332.
  • 26
    Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005; 41: 2807.
  • 27
    Hays RD, Hadorn D. Responsiveness to change: an aspect of validity, not a separate dimension. Qual Life Res 1992; 1: 735.
  • 28
    Hays RD. Reliability and validity (including responsiveness). In: FayersP, HaysRD, editors. Assessing quality of life in clinical trials: methods and practice. 2nd ed. New York: Oxford University Press; 2005. p. 2539.
  • 29
    Liang K, Zegar S. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 1323.
  • 30
    Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 96374.
  • 31
    Franzblau A. A primer of statistics for non-statisticians. New York: Harcourt, Brace & World; 1958.
  • 32
    Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 56: 395407.
  • 33
    Cohen J. A power primer. Psychol Bull 1992; 112: 1559.
  • 34
    Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005; 14: 28595.
  • 35
    Osoba D, Brada M, Yung WK, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 2000; 36: 178895.
  • 36
    Cole JC, Motivala SJ, Khanna D, Lee JY, Paulus HE, Irwin MR. Validation of single-factor structure and scoring protocol for the Health Assessment Questionnaire-disability index. Arthritis Rheum 2005; 53: 53642.
  • 37
    Cole JC, Khanna D, Clements PJ, Seibold JR, Tashkin DP, Paulus HE, et al. Single-factor scoring validation for the Health Assessment Questionnaire-disability index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res 2006; 15: 138394.
  • 38
    Nich C, Carroll KM. Intention-to-treat meets missing data: implications of alternate strategies for analyzing clinical trials data. Drug Alcohol Depend 2002; 68: 12130.
  • 39
    Jorgensen B, Tsao M. Dispersion models and longitudinal data analysis [review]. Stat Med 1999; 18: 225770.
  • 40
    Walter SD. Number needed to treat (NNT): estimation of a measure of clinical benefit. Stat Med 2001; 20: 394762.
  • 41
    Manne SL, Zautra AJ. Coping with arthritis: current status and critique [review]. Arthritis Rheum 1992; 35: 127380.
  • 42
    Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life [review]. Ann Intern Med 1993; 118: 6229.
  • 43
    Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA 1995; 273: 5965.
  • 44
    Gliddon AE, Dore CJ, Maddison PJ, and the QUINS Trial Study Group. Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis. Arthritis Rheum 2006; 55: 4739.
  • 45
    Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 565: 395407.
  • 46
    Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: another step toward consensus [editorial]. J Clin Epidemiol 2005; 58: 12179.
  • 47
    Farivar S, Liu H, Hays RD. Half standard deviation estimate of the minimally important difference in health-related quality of life scores? Expert Rev Pharmacoecon Outcomes Res 2004; 4: 51523.
  • 48
    Mahler DA, Matthay RA, Snyder PE, Wells CK, Loke J. Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis 1985; 131: 225.
  • 49
    Hay JG, Stone P, Carter J, Church S, Eyre-Brook A, Pearson MG, et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992; 5: 65964.
  • 50
    Bellia V, Foresi A, Bianco S, Grassi V, Olivieri D, Bensi G, et al. Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: a double-blind, randomized, multicentre study (BREATH Trial). Respir Med 2002; 96: 8819.
  • 51
    Weinstein MC, Siegel JE, Gold MR, Kamlet M, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine [review]. JAMA 1996; 276: 12538.
  • 52
    Martinez TY, Pereira CA, dos Santos ML, Ciconelli RM, Guimaraes SM, Martinez JA. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest 2000; 117: 162732.